Information:
Fel:
ID
32683
Beskrivning
Study ID: 107038 Clinical Study ID: LPL107038 Study Title: Study to Estimate the Dose Proportionality of the Enteric-Coated Freebase Formulation of SB-480848 Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: Tyrisa ,US Study Indication: Atherosclerosis
Nyckelord
Versioner (1)
- 2018-11-12 2018-11-12 -
Rättsinnehavare
GSK group of companies
Uppladdad den
12 november 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Estimation of Dose Proportionality of Darapladib - 107038
Similar models
Eligibility Question
- StudyEvent: ODM
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Did the subject meet all the entry criteria?
Item
Did the subject meet all the entry criteria?
boolean
Do not admit he subject into this study if any Inclusion/Exclusion criteria is violated unless an exception has been granted by the GSK Medical Monitor and subject is continuing in the study. Please clarify the exemption(s) below
Item
Do not admit he subject into this study if any Inclusion/Exclusion criteria is violated unless an exception has been granted by the GSK Medical Monitor and subject is continuing in the study. Please clarify the exemption(s) below
text
Inga kommentarer